Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”

Detalles Bibliográficos
Autores principales: Picardi, Marco, Giordano, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018111/
https://www.ncbi.nlm.nih.gov/pubmed/33792226
http://dx.doi.org/10.3324/haematol.2020.278203
_version_ 1783674160189276160
author Picardi, Marco
Giordano, Claudia
author_facet Picardi, Marco
Giordano, Claudia
author_sort Picardi, Marco
collection PubMed
description
format Online
Article
Text
id pubmed-8018111
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-80181112021-04-05 Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.” Picardi, Marco Giordano, Claudia Haematologica Comment Fondazione Ferrata Storti 2021-04-01 /pmc/articles/PMC8018111/ /pubmed/33792226 http://dx.doi.org/10.3324/haematol.2020.278203 Text en Copyright© 2021 Ferrata Storti Foundation http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Comment
Picardi, Marco
Giordano, Claudia
Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”
title Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”
title_full Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”
title_fullStr Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”
title_full_unstemmed Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”
title_short Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.”
title_sort comment on “combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory hodgkin lymphoma: the phase ii hovon/llpc transplant brave study.”
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018111/
https://www.ncbi.nlm.nih.gov/pubmed/33792226
http://dx.doi.org/10.3324/haematol.2020.278203
work_keys_str_mv AT picardimarco commentoncombiningbrentuximabvedotinwithdexamethasonehighdosecytarabineandcisplatinassalvagetreatmentinrelapsedorrefractoryhodgkinlymphomathephaseiihovonllpctransplantbravestudy
AT giordanoclaudia commentoncombiningbrentuximabvedotinwithdexamethasonehighdosecytarabineandcisplatinassalvagetreatmentinrelapsedorrefractoryhodgkinlymphomathephaseiihovonllpctransplantbravestudy

Ejemplares similares